Finch Therapeutics

The Ides of March bring no misfortune to biotech, as industry logs second-busiest IPO week of 2021
The Ides of March bring no misfortune to biotech, as industry logs second-busiest IPO week of 2021
Endpoints
IPOs
NASDAQ
Instil Bio
Connect Biopharma
Finch Therapeutics
Gain Therapeutics
Flag link:
Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
Endpoints
IPOs
SPAC
Finch Therapeutics
microbiome
Connect Biopharma
Insil Bio
Transcode Therapeutics
Flag link:
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline
Xconomy
microbiome
Finch Therapeutics
Seres Therapeutics
Flag link:
In big year for microbiome drugs, a small biotech sets the bar
In big year for microbiome drugs, a small biotech sets the bar
BioPharma Dive
biotech
microbiome
Finch Therapeutics
C. difficile
Flag link:
Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease
Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease
Endpoints
Takeda
Finch Therapeutics
microbiome
Crohn's Disease
Flag link:
Microbiome Report
Microbiome Report
CP Wire
microbiome
Finch Therapeutics
Scioto Biosciences
Flag link:
Microbiome Report
microbiome
Finch Therapeutics
Scioto Biosciences
Flag link:
Microbiome company Finch raises $53M ahead of anti-infective readout
Microbiome company Finch raises $53M ahead of anti-infective readout
BioCentury
microbiome
Finch Therapeutics
C. difficile
Flag link:
Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
CP Wire
Finch Therapeutics
CP101
C. difficile
microbiome
Flag link:
Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
Finch Therapeutics
CP101
C. difficile
microbiome
Flag link:
Microbiome Report for the week ending 7-29-18
Microbiome Report for the week ending 7-29-18
CP Wire
microbiome
Finch Therapeutics
patents
Qu Biologics
Crohn’s disease
Alzheimer's disease
Flag link:
Microbiome Report for the week ending 7-29-18
microbiome
Finch Therapeutics
patents
Qu Biologics
Crohn’s disease
Alzheimer's disease
Flag link:
Finch Therapeutics Expands Microbiome IP Portfolio with Six New Patents
Finch Therapeutics Expands Microbiome IP Portfolio with Six New Patents
CP Wire
Finch Therapeutics
microbiome
patents
Flag link:
Finch Therapeutics Expands Microbiome IP Portfolio with Six New Patents
Finch Therapeutics
microbiome
Flag link:
Takeda-partnered Finch Therapeutics grabs $36M and looks to leapfrog the pack in microbiome R&D
Takeda-partnered Finch Therapeutics grabs $36M and looks to leapfrog the pack in microbiome R&D
Endpoints
Takeda
Finch Therapeutics
microbiome
R&D
Flag link:
Takeda partner Finch joins forces with Crestovo, leaping into a late-stage microbiome study
Takeda partner Finch joins forces with Crestovo, leaping into a late-stage microbiome study
Endpoints
Takeda
Finch Therapeutics
Crestovo
C. difficile
microbiome
CP101
Flag link: